Yahoo Finance 
Global In Vitro Diagnostics Partnering Deals Directory 2014-2020: Company A-Z, Headline Value, Stage of Development at Signing, Deal Component Type, Specific Therapy Target, Technology Type
Dublin, March 29, 2021 (GLOBE NEWSWIRE) -- The "Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2020" report has been added to ResearchAndMarkets.com's offering.
The Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2020 report provides comprehensive access to available deals and contract documents for over 550 In Vitro Diagnostics deals.
These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest In Vitro Diagnostics agreements announced in the life sciences since 2014.
The report takes the reader through a comprehensive review In Vitro Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering In Vitro Diagnostics partnering deals.
The report presents financial deal term values for In Vitro Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the In Vitro Diagnostics partnering field; both the leading deal values and most active In Vitro Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 550 online deal records of actual In Vitro Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
A comprehensive series of appendices is provided organized by In Vitro Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of In Vitro Diagnostics technologies and products.
Key benefits
In Vitro Diagnostics Partnering Terms and Agreements includes:
Trends in In Vitro Diagnostics dealmaking in the biopharma industry since 2014
Analysis of In Vitro Diagnostics deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life In Vitro Diagnostics deals
Access to In Vitro Diagnostics contract documents
Leading In Vitro Diagnostics deals by value since 2014
Most active In Vitro Diagnostics dealmakers since 2014
In Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2020, the available deals are listed by:
Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Technology type
Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in In Vitro Diagnostics dealmaking
2.1. Introduction
2.2. In Vitro Diagnostics partnering over the years
2.3. Most active In Vitro Diagnostics dealmakers
2.4. In Vitro Diagnostics partnering by deal type
2.5. In Vitro Diagnostics partnering by therapy area
2.6. Deal terms for In Vitro Diagnostics partnering
Chapter 3 - Leading In Vitro Diagnostics deals
3.1. Introduction
3.2. Top In Vitro Diagnostics deals by value
Chapter 4 - Most active In Vitro Diagnostics dealmakers
4.1. Introduction
4.2. Most active In Vitro Diagnostics dealmakers
4.3. Most active In Vitro Diagnostics partnering company profiles
Chapter 5 - In Vitro Diagnostics contracts dealmaking directory
5.1. Introduction
5.2. In Vitro Diagnostics contracts dealmaking directory
Chapter 6 - In Vitro Diagnostics dealmaking by technology type
Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendices
Appendix 1 - In Vitro Diagnostics deals by company A-Z
Appendix 2 - In Vitro Diagnostics deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
Appendix 3 - In Vitro Diagnostics deals by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty
Appendix 4 - In Vitro Diagnostics deals by therapy area
Appendix 5 -Deal type definitions
For more information about this report visit https://www.researchandmarkets.com/r/c279pm
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
